Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

293
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
293
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.0K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

867
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
867
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

334
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
334
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyunsaturated Fatty Acid Balance Modulates Microglial State in a Murine Model of Oxygen-Induced Neovascularization.

Nutrients·2026
Same author

Canadian Stroke Best Practice Recommendations: Rehabilitation, Recovery and Community Participation Following Stroke. Part One: Stroke Rehabilitation Planning for Optimal Care Delivery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Two: Delivery of Stroke Rehabilitation to Optimize Functional Recovery, 7th Edition Update 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Canadian Stroke Best Practice Recommendations Rehabilitation, Recovery, and Community Participation Following Stroke, Part Three: Optimizing Activity and Community Participation Following Stroke , 7th Edition Update, 2025.

American journal of physical medicine & rehabilitation·2025
Same author

Polyunsaturated fatty acid balance modulates microglial state in a murine model of oxygen-induced neovascularization.

Research square·2025
Same author

Outcomes of an App-Based Intervention to Target Naming Among Individuals With Poststroke Aphasia: Virtual Randomized Controlled Trial.

JMIR mHealth and uHealth·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.7K

Valbenazine: First Global Approval.

Esther S Kim1

  • 1Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand. dru@adis.com.

Drugs
|June 5, 2017
PubMed
Summary
This summary is machine-generated.

Valbenazine (Ingrezza™) is a selective VMAT2 inhibitor approved in the USA for tardive dyskinesia (TD). This article details its development milestones leading to this significant regulatory approval for TD treatment.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.7K

Related Experiment Videos

Last Updated: Mar 1, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.7K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K
The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.7K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Tardive dyskinesia (TD) is a hyperkinetic movement disorder often associated with long-term antipsychotic use.
  • Current treatment options for TD have limitations, creating a need for effective therapies.

Purpose of the Study:

  • To summarize the key development milestones of valbenazine (Ingrezza™).
  • To highlight the regulatory pathway leading to its US approval for tardive dyskinesia.

Main Methods:

  • Review of preclinical and clinical development data for valbenazine.
  • Analysis of regulatory submissions and approvals.

Main Results:

  • Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, demonstrated efficacy in treating tardive dyskinesia.
  • The drug received US FDA approval for adults with TD.

Conclusions:

  • Valbenazine represents a significant advancement in the treatment of tardive dyskinesia.
  • The development journey highlights successful progression from research to regulatory approval.